Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
0.3119
+0.0054 (1.76%)
Jun 23, 2025, 4:00 PM - Market closed
Rallybio Revenue
Rallybio had revenue of $212.00K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $848.00K. In the year 2024, Rallybio had annual revenue of $636.00K.
Revenue (ttm)
$848.00K
Revenue Growth
n/a
P/S Ratio
16.38
Revenue / Employee
$33,920
Employees
25
Market Cap
12.98M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RLYB News
- 12 days ago - Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - Business Wire
- 6 weeks ago - Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 2 months ago - Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference - Business Wire
- 2 months ago - Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints - Benzinga
- 2 months ago - Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT - Business Wire
- 3 months ago - Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - Business Wire
- 4 months ago - Rallybio to Present at the TD Cowen 45th Annual Health Care Conference - Business Wire
- 4 months ago - Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - Business Wire